

Histo-Molecular Factors of Response to Combined Chemotherapy and Immunotherapy in Non-small cell Lung Cancers

Marchal Marine¹ ; Leroy Vincent² ; Behal H  l  ne³ ; Dansin Eric⁴ ; Paris Nicolas⁵ ; Bordier Soraya⁶ ; Humez Sarah^{7,8} ; Escande Fabienne⁹ ; Gauvain Cl  ment¹ ; Cortot Alexis B.^{1,8}

¹ Univ. Lille, CHU Lille, Department of Thoracic Oncology, Lille, France;

² Department of Pneumology, Clinique Tessier, Valenciennes, France;

³ CHU Lille, Biostatistics Department, Lille, France;

⁴ Department of Medical Oncology, Centre Oscar Lambret, Lille, France;

⁵ Department of Pneumology, Dunkerque Hospital, Dunkerque, France;

⁶ Department of Pneumology, Roubaix Hospital, Roubaix, France;

⁷ Univ. Lille, CHU de Lille, Department of Pathology, Lille, France;

⁸ Univ. Lille, CHU Lille, CNRS, Inserm, Institut Pasteur de Lille, UMR9020 – UMR1277 – Canther – Cancer Heterogeneity, Plasticity and Resistance to Therapies, Lille, France;

⁹ Univ. Lille, CHU de Lille, Department of Biochemistry and Molecular Biology, Lille, France.

Corresponding author:

Marine Marchal

CHU Lille, Thoracic Oncology Department

Boulevard du Professeur Leclercq, 59000, Lille, France


Tel: +33 3 20 44 56 12

Fax: +33 3 20 44 56 11

Email: marine.marchal@chu-lille.fr


SUPPLEMENTARY MATERIEL

Supplementary Figure A




A. Flowchart of the study population (A1) and distribution of oncogenic drivers subgroups (A2)

Supplementary Figure B




B. Kaplan-Meier curves of progression-free survival in EGFR/ALK/ROS1/RET subgroup and in other patients

Supplementary Figure C




C. Kaplan-Meier curves of progression-free survival in KRAS subgroup and in other patients

Supplementary Figure D



D. Kaplan-Meier curves of progression-free survival in BRAF subgroup and in other patients


Supplementary Figures E



E. Kaplan-Meier curves of progression-free survival (E1) and overall survival (E2) according to inactivating TP53 mutations.

TP53m, TP53-mutated patients; TP53wt, TP53 wild-type patients

Supplementary Figure F



F. Kaplan-Meier curves of progression-free survival according to smoking status
PY, pack-years